Increasing evidence suggests that the SYT-SSX fusion gene plays an important role in synovial sarcoma development and progression. However, very little is known about the downstream targets of SYT-SSX. In this study, we used antisense oligonucleotides to block the expression of the SYT-SSX fusion gene in synovial sarcoma cells. By comparing SYT-SSX inhibited cells with noninhibited cells, the gene expression profile was analysed using cDNA microarray and established by realtime PCR. Herewith, using a filter containing 1176 cancer-relevant genes, we found that the DNA repair gene XRCC4 and the DNA mismatch repair gene MSH2 were downregulated, whereas the gene encoding for the serine/threonine protein kinase PRK (also known as CNK), and the macrophage inhibitory cytokine MICI (also known as PLAB) were upregulated after the inhibition of SYT-SSX. In comparison, expression of the XRCC4 gene was undergoing the strongest alteration. Consistently, the protein expression of XRCC4 was found to be decreased after SYT-SSX inhibition, whereas there were no detectable changes for the other gene products. Our study provides some clues to elucidate the signaling pathways of the SYT-SSX fusion gene, as well as it demonstrates a valuable model system for search for other SYT-SSX targets.
Increasing evidence suggests that the SYT-SSX fusion gene plays an important role in synovial sarcoma development and progression. However, very little is known about the downstream targets of SYT-SSX. In this study, we used antisense oligonucleotides to block the expression of the SYT-SSX fusion gene in synovial sarcoma cells. By comparing SYT-SSX inhibited cells with noninhibited cells, the gene expression profile was analysed using cDNA microarray and established by realtime PCR. Herewith, using a filter containing 1176 cancer-relevant genes, we found that the DNA repair gene XRCC4 and the DNA mismatch repair gene MSH2 were downregulated, whereas the gene encoding for the serine/threonine protein kinase PRK (also known as CNK), and the macrophage inhibitory cytokine MICI (also known as PLAB) were upregulated after the inhibition of SYT-SSX. In comparison, expression of the XRCC4 gene was undergoing the strongest alteration. Consistently, the protein expression of XRCC4 was found to be decreased after SYT-SSX inhibition, whereas there were no detectable changes for the other gene products. Our study provides some clues to elucidate the signaling pathways of the SYT-SSX fusion gene, as well as it demonstrates a valuable model system for search for other SYT-SSX targets. Oncogene (2003 Oncogene ( ) 22, 7628-7631. doi:10.1038 Keywords: microarray; antisense; SYT-SSX; synovial sarcoma Synovial sarcoma is a highly malignant soft-tissue sarcoma, which mainly affects adolescents and young adults. The chromosome translocation t(X;18) (p11.2,q11.2) is specific for synovial sarcoma, and fuses the SYT gene on chromosome 18 to either the SSX1 or SSX2, or rarely SSX4 gene on the X chromosome, resulting in SYT-SSX1, SYT-SSX2 or rarely SYT-SSX4 fusion gene (Clark et al., 1994; Crew et al., 1995; de Leeuw et al., 1995; Skytting et al., 1999) .
The function of the SYT-SSX fusion gene is largely unknown, but substantial evidence indicates that the fusion gene may play an important role in synovial sarcoma development and progression (dos Santos et al., 2001; Ladanyi, 2001 ). The fusion protein contains both potential transcription activating and repressing domains, but lacks DNA-binding motifs, suggesting that it may act as a transcriptional regulator through interaction with other proteins (Brett et al., 1997; Thaete et al., 1999) . Although downstream pathways of the SYT-SSX fusion gene still have not been identified, previous studies have suggested that SYT-SSX is involved in the regulation of synovial sarcoma cell growth Inagaki et al., 2000; Xie et al., 2002a) . A recent study of ours provided evidence that expression of the SYT-SSX fusion gene stabilizes the cyclin D1 protein. Using an antisense strategy, a specific inhibition of the fusion gene led to a rapid (within 3 h) and drastic cyclin D1 decline and eventually to inhibited cell growth (Xie et al., 2002b) . This finding highlighted the involvement of SYT-SSX in the cell cycle machinery.
The aforementioned antisense strategy to block specifically the SYT-SSX fusion gene in human synovial sarcoma cells may provide an ideal platform to identify new downstream targets and signaling pathways of the fusion gene. One approach is to apply the relatively new cDNA array technology on this experimental model. This technology has recently been used in a study of SYT-SSX1 expression in a tetracycline-off system, where downregulation of the potential tumor suppressor gene product DCC was observed (Nagai et al., 2001) .
In the present study, we used cDNA array and realtime PCR to investigate gene expression profile in synovial sarcoma cells after antisense treatment. We aimed to evaluate the utility of the antisense model and to find some clues for a better understanding of the molecular pathogenesis of the SYT-SSX fusion gene.
The human synovial sarcoma cells (1273/99), cultured in large dishes, were treated by antisense-ODNs (As-ODNs) or mismatch-ODNs (Mis-ODNs) or Lipofectin alone (untreated control cells) for 14 h. Samples were taken for analysis of SYT-SSX and cyclin D1 expression. It is demonstrated that As-ODN inhibits SYT-SSX fusion gene expression, as assessed by semiquantitative RT-PCR. In contrast, Lipofectin alone and Mis-ODN had no effects on the expression of SYT-SSX (Figure 1a) . It is not possible to assay the endogenous (nontagged) SYT-SSX protein because specific antibodies are still not available (either commercially or noncommercially). Instead, the inhibition of the SYT-SSX expression can be assessed by the determination of the cyclin D1 protein expression, as demonstrated elsewhere (Xie et al., 2002b) . In parallel to the inhibition of SYT-SSX expression, we could also verify that As-ODN induced a substantial decrease in cyclin D1 expression, whereas it remained unchanged after Mis-ODN or Lipofectin treatment ( Figure 1b) . These results were fully consistent with our previous findings that SYT-SSX is obligatory for cyclin D1 expression (Xie et al., 2002b ).
The remaining and major part of the aforementioned 1273/99 cell cultures, treated with As-ODN or Mis-ODN for 14 h and confirmed for adequate response of SYT-SSX and cyclin D1 expression (Figure 1 ), was subjected to isolation of total RNA and cDNA array analysis. Untreated (Lipofectin) cells were considered as a reference. We found that eight genes altered their expression significantly in the As-ODN-treated cells, either by upregulation or downregulation (Table 1) . In contrast, Mis-ODN treatment was without any effects and did not differ from untreated control cells (data not shown). Since Mis-ODN to date is the best control for antisense treatment settings (Myers and Dean, 2000) , this control is very important to exclude any nonspecific effects due to oligonucleotides per se. Consequently, we can conclude that the altered expression of these eight genes, as assayed by microarray, was due to inhibited SYT-SSX expression. Interestingly, these genes cover important cancer-relevant functions like cell proliferation, apoptosis and DNA repair. It should also be added here that we also analysed the effects of a short treatment of As-ODN (3 h), but no significant changes in the gene profile could then be observed (data not shown).
In order to confirm the microarray data, real-time PCR was performed to analyse the expression of these eight genes on the same RNA as used for the array. All eight genes, except the caspase-10 precursor, were successfully amplified. The primers for real-time PCR are presented in Table 2 . By comparing the As-ODN and Mis-ODN treatments, we found that the gene expression of the putative serine/threonine protein kinase PRK and macrophage inhibitory cytokine MIC1 was upregulated, and that the gene expression of DNA repair protein XRCC4, the DNA mismatch repair protein MSH2 and the matrix metalloproteinase MMP2 was downregulated (Table 1) . Among these changes, the downregulation of the XRCC4 gene was the strongest one (10.8-fold difference). The remaining two genes (NIK and WIP1) did not exhibit any differences between the As-and Mis-ODN-treated samples (Table 1) .
We also investigated the protein expression of the aforementioned genes by Western blotting. In Figure 2a , it is shown that a 24 h treatment with SYT-SSXAs-ODN did not change the expression of MMP2, NIK and PRK in the two synovial sarcoma cells 1273/99 and CME-1, whereas cyclin D1 was adequately decreased. We also tested the protein expression of MSH2, MIC1 and WIP1, but none of these was altered either (data not shown). In contrast, SYT-SSX inhibition caused a clear decrease in XRCC4 expression in both 1273/99 and CME-1 (Figure 2a) . As a control we also analysed the effect of As-ODN on non-SYT-SSX cells (i.e. Ewing's sarcoma cell line RD-ES), which expresses SYT but not SYT-SSX (Xie et al., 2002b) . As clearly demonstrated in Figure 2b , neither the expression of cyclin D1 nor XRCC4 was affected by As-ODN treatment. This result confirms that the decrease in XRCC4 is due to inhibition of the fusion gene and not of the wild-type SYT. harbors the SYT-SSX2 fusion gene. The As-ODN treatment of 1273/99 cells was performed as described previously (Xie et al., 2002b) . In brief, a 25-mer As-ODN that targets the SYT-SSX fusion gene covers the ATG start-codon of SYT mRNA. A 10-mer Mis-ODN was used as a control; bases in bold font indicate substitutions. The ODNs were phosphorothiolated and purchased from Invitrogen (UK). As-ODN: CCACAGACATG TTGCCGCCCATCCA and Mis-ODN: CAGCCAACATG CCGTTGCCCACCTA. 1273/99 cells were cultured in 100-mm dishes. When the cells reached 40-60% confluence, they were treated with 0.5 mM SYT-SSXAs-ODN or SYT-SSXMis-ODN mixed with 10 mg/ml Lipofectin (Invitrogen UK) in serum-free F-12 medium for 4 h, after which the ODN-medium mixture was replaced with F-12 medium supplemented with 20% FBS. Cells were harvested for analysis at indicated time. Semiquantitative RT-PCR and Western blotting are described elsewhere (Xie et al., 2002b) . 1273/99 cells were treated with Lipofectin alone, SYTSSXAs-ODN or SYT-SSXMis-ODN for 14 h. (a) SYT-SSX mRNA was detected by semiquantitative RT-PCR, using actin as an internal control. (b) Cyclin D1 protein was determined by Western blotting (Xie et al., 2002b) . Actin was used as loading control
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We also tried to assay the effect of As-ODN for SYT-SSX on XRCC4 in mouse cells (NIH3T3) transfected with SYT-SSX. Whereas we could verify that As-ODN treatment inhibited cyclin D1 expression, we could not find any detectable expression of XRCC4 in the NIH3T3 cells (data not shown).
Based on this cDNA microarray gene profile assay, we can conclude that XRCC4 was of special interest, since it underwent the strongest alteration assayed by real-time PCR as well as it was the only gene undergoing detectable changes at protein expression level following SYT-SSX inhibition. The other genes, detected by the array as SYT-SSX dependent, exhibited only weak or moderate changes at transcriptional level and no alteration at protein level as assayed by real-time PCR and Western blotting, respectively. However, this does not preclude that at least some of them (e.g. PRK and MSH2) are dependent on SYT-SSX. Perhaps, much longer periods of fusion gene inhibition would affect their protein expression.
In eukaryotic cells two main pathways, nonhomologous end joining (NHEJ) and homologous recombination exist to repair the double-strand breaks (DSBs) (Ferguson and Alt, 2001; Khanna and Jackson, 2001 ). In fact, spontaneous DSBs occur frequently in normally dividing cells and these two pathways are crucial for their repair. Therefore, they play a vital role in maintaining the genomic stability, and either pathway deficiency may lead to genomic instability, such as deletions, insertions or translocations (Ferguson and Alt, 2001; Khanna and Jackson, 2001 ). a Total RNA was isolated using Qiagen RNeasy kit (Qiagen, Hilden, Germany) after 14 h As-or Mis-ODNs treatment. Human Cancer 1.2 Arrays Filters containing 1176 genes was purchased from Clontech (Germany). The probes labelling and hybridization were performed according to the manufacturer's instructions. In brief, 3 mg total RNA was converted into cDNA and labelled with [ 33 P]dATP using the Clontech cDNA array labelling kit. The cDNA probes were then hybridized to the array filters. After washing the filters were exposed to imaging plates (BAS-MP 2040S; Fuji, Kanagawa, Japan) and scanned by a phosphorimager (Bio-Imaging Analyzer, BAS-2500; Fuji) with high-resolution (16 bit) tiff-format images. The images were imported and analysed using Atlas image analysis software (Clontech). To ensure the optimum quality of the hybridizations, one filter was maximally used twice. In order to confirm the reproducibility of the results, each sample was hybridized twice with different filters. The two independent hybridization images were then compared to each other using the Atlas Image software (Clontech) to avoid any misinterpretation. In our analysis, we divided genes into two categories according to their expression ratios (treated/untreated cells), upregulated (ratio X2.0) and downregulated (ratio p0.5).
b Signal intensity of genes from treated cells/signal intensity of genes from untreated ( ¼ Lipofectin-treated) cells.
c A measure of 0.5 mg of DNase-1-treated total RNA was reversed to cDNA by using first-strand cDNA synthesis kit (Roche, Mannheim, Germany). The PCR primers (TIB MOLBIOL Germany) are presented in Table 2 . Standard curves were obtained by using serial dilutions of beta-globulin gene (DNA Control kit, Roche). PCR solution contains one mixture (DNA Fast Start Master SYBR Green 1 mix, Roche) with 1 ml of cDNA and 5-10 pmol of the primers. The PCR process was started at 951C for 12 min, then followed 45 cycles at 951C for 10 s, 60-651C for 5 s and 721C for 10-20 s. Amplifications were followed by melting curve analysis using one cycle at 981C with 0 s hold, 651C with 10 s hold and 951C with 0 s hold in the acquisition step mode. A negative control without cDNA template was run with every assay. The expression of each gene was determined on the basis of kinetic approach using the LightCycler software. XRCC4, a new identified genomic caretaker, is involved in the NHEJ DNA repair pathway (Roth and Gellert, 2000) . In addition to massive apoptosis during nervous system development in XRCC4-deficient mice, the embryos were also growth retarded and their fibroblasts exhibited decreased proliferation and premature senescence in culture (Gao et al., 1998 (Gao et al., , 2000 . The increased neuronal apoptosis and cellular proliferation defects of XRCC4-deficient mice was found to be p53 dependent (Gao et al., 2000) .
Notably, inhibition of SYT-SSX fusion gene led to a substantial decrease in the expression of XRCC4 in synovial sarcoma cells. As a DNA damage response would be likelier due to impaired repair following XRCC4 depletion, this might eventually activate the p53 checkpoint pathway to induce growth arrest or apoptosis. This hypothesis, at least in part, is consistent with our findings that synovial sarcoma cells finally undergo apoptosis after the inhibition of the SYT-SSX fusion gene (unpublished data).
In conclusion, our study provides some clues to elucidate the signaling pathways of the SYT-SSX fusion gene. Especially, further studies to confirm and explore the role of XRCC4 in synovial sarcoma will be of interest. In addition, the antisense model presented here might be an important tool for identifying other genes and molecules dependent on SYT-SSX. 
